Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 18/20 | 0.68 |
| ▸ | ESR2 | Q92731 | 4/20 | 0.56 |
| ▸ | XDH | P47989 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14428674 | 1.00 | ESR1 (0.68) | ESR1ESR2XDH | |
| SCHEMBL14622402 | 0.91 | ESR1 (0.77) | ESR1ESR2 | |
| SCHEMBL4641975 | 0.91 | ESR1 (0.68) | ESR1ESR2 | |
| SCHEMBL14506973 | 0.91 | ESR1 (0.68) | ESR1ESR2 | |
| SCHEMBL6810576 | 0.90 | ESR1 (0.68) | ESR1ESR2 | |
| Hydrochloric Acid SCHEMBL5417631 | 0.90 | ESR1 (0.67) | ESR1ESR2 | |
| SCHEMBL14622403 | 0.89 | ESR1 (0.65) | ESR1ESR2 | |
| SCHEMBL4640166 | 0.88 | ESR1 (0.65) | ESR1ESR2 | |
| SCHEMBL6744378 | 0.87 | ESR1 (0.58) | ESR1ESR2XDH | |
| Hydrochloric Acid SCHEMBL6749894 | 0.86 | ESR1 (0.59) | ESR1ESR2XDH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1450812-A4 | USE OF BENZOPYRANONES FOR TREATING OR PREVENTING A PRIMARY BRAIN CANCER OR A BRAIN METASTASIS | SIGNAL PHARM INC (US) | 2007-03-28 | — | — | EP | disclosed |
| US-7148252-B2 | Use of benzopyranones for treating or preventing a primary brain cancer or a brain metastasis | SIGNAL PHARMACEUTICALS, LLC (US) | 2006-12-12 | — | — | US | disclosed |
| EP-1246814-B1 | COMPOUNDS AND METHODS FOR MODULATION OF ESTROGEN RECEPTORS | SIGNAL PHARM INC (US) | 2005-02-16 | — | — | EP | disclosed |
| EP-1450812-A2 | USE OF BENZOPYRANONES FOR TREATING OR PREVENTING A PRIMARY BRAIN CANCER OR A BRAIN METASTASIS | Signal Pharmaceuticals, Inc. (US) | 2004-09-01 | — | — | EP | disclosed |
| EP-1140889-B1 | COMPOUNDS AND METHODS FOR MODULATION OF ESTROGEN RECEPTORS | SIGNAL PHARM INC (US) | 2003-08-27 | — | — | EP | disclosed |
| US-20030149025-A1 | Use of benzopyranones for treating or preventing a primary brain cancer or a brain metastasis | SIGNAL PHARMACEUTICALS, INC. | 2003-08-07 | — | — | US | disclosed |
| WO-2003028652-A2 | USE OF BENZOPYRANONES FOR TREATING OR PREVENTING A PRIMARY BRAIN CANCER OR A BRAIN METASTASIS | SIGNAL PHARMACEUTICALS, INC. (US) | 2003-04-10 | — | — | WO | disclosed |
| US-6372739-B1 | COUMARONE DERIVATIVES FOR DRUGS | SIGNAL PHARMACEUTICALS, INC. | 2002-04-16 | — | — | US | disclosed |
| US-6331562-B1 | SELECTIVELY MODULATE ESTROGEN RECEPTOR-BETA ACTIVITY; INHIBIT CYTOKINES SUCH AS INTERLEUKIN-6 | SIGNAL PHARMACEUTICALS, INC. | 2001-12-18 | — | — | US | disclosed |
| EP-1140889-A2 | COMPOUNDS AND METHODS FOR MODULATION OF ESTROGEN RECEPTORS | SIGNAL PHARMACEUTICALS, INC. (US) | 2001-10-10 | — | — | EP | disclosed |
| US-6291456-B1 | Compounds and methods for modulation of estrogen receptors | SIGNAL PHARMACEUTICALS, INC. | 2001-09-18 | — | — | US | disclosed |
| WO-2000039120-A2 | COMPOUNDS AND METHODS FOR MODULATION OF ESTROGEN RECEPTORS | SIGNAL PHARMACEUTICALS, INC. (US) | 2000-07-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030149025-A1 | Use of benzopyranones for treating or preventing a primary brain cancer or a brain metastasis | RB1, FOXK1, SKP1 | ESR1 2470/4885ESR2 1390/4885XDH 661/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.